MRNA Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -121.83% compared to Moderna, Inc.'s net margin of 27.44%. Moderna, Inc.'s return on equity of -29.19% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Moderna, Inc. has a consensus price target of $42.90, signalling downside risk potential of -23.35%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $156.59 which suggests that it could grow by 7.26%. Given that Gilead Sciences, Inc. has higher upside potential than Moderna, Inc., analysts believe Gilead Sciences, Inc. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.291, which suggesting that the stock is 29.087% more volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.44%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.16% to investors and pays a quarterly dividend of $0.79 per share. Moderna, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.6% of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $8B. Moderna, Inc.'s net income of -$826M is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 21.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 11.20x versus 6.22x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -121.83% compared to Moderna, Inc.'s net margin of 20.83%. Moderna, Inc.'s return on equity of -29.19% beat Johnson & Johnson's return on equity of 34.46%.

Moderna, Inc. has a consensus price target of $42.90, signalling downside risk potential of -23.35%. On the other hand Johnson & Johnson has an analysts' consensus of $238.29 which suggests that it could fall by -1.93%. Given that Moderna, Inc. has more downside risk than Johnson & Johnson, analysts believe Johnson & Johnson is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.291, which suggesting that the stock is 29.087% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.338, suggesting its less volatile than the S&P 500 by 66.17%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.14% to investors and pays a quarterly dividend of $1.30 per share. Moderna, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Moderna, Inc.'s net income of -$826M is lower than Johnson & Johnson's net income of $5.1B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 22.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 11.20x versus 6.26x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -121.83% compared to Moderna, Inc.'s net margin of 34.4%. Moderna, Inc.'s return on equity of -29.19% beat Eli Lilly & Co.'s return on equity of 104.39%.

Moderna, Inc. has a consensus price target of $42.90, signalling downside risk potential of -23.35%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,216.93 which suggests that it could grow by 21.71%. Given that Eli Lilly & Co. has higher upside potential than Moderna, Inc., analysts believe Eli Lilly & Co. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.291, which suggesting that the stock is 29.087% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.355%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Moderna, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Moderna, Inc.'s net income of -$826M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 44.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 11.20x versus 13.97x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -121.83% compared to Moderna, Inc.'s net margin of 18.15%. Moderna, Inc.'s return on equity of -29.19% beat Merck & Co., Inc.'s return on equity of 36.76%.

Moderna, Inc. has a consensus price target of $42.90, signalling downside risk potential of -23.35%. On the other hand Merck & Co., Inc. has an analysts' consensus of $127.22 which suggests that it could grow by 9.48%. Given that Merck & Co., Inc. has higher upside potential than Moderna, Inc., analysts believe Merck & Co., Inc. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.291, which suggesting that the stock is 29.087% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.269, suggesting its less volatile than the S&P 500 by 73.077%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.82% to investors and pays a quarterly dividend of $0.85 per share. Moderna, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Moderna, Inc.'s net income of -$826M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 15.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 11.20x versus 4.49x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.